Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis (Q30251450)

13 June 2017

1 reference

1 reference

1 reference

title

Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis (English)

1 reference

chronic renal insufficiency

13 June 2017

main subject

1 reference

9

Lehana Thabane

1 reference

13 June 2017

Jason W Busse

2

0 references

Gordon Guyatt

8

object named as

Gordon H Guyatt

1 reference

13 June 2017

7

Reem A Mustafa

1 reference

13 June 2017

Nigar Sekercioglu

1

1 reference

13 June 2017

M Fatih Sekercioglu

3

1 reference

13 June 2017

Arnav Agarwal

4

1 reference

13 June 2017

Shaun Shaikh

5

1 reference

13 June 2017

Luciane Cruz Lopes

6

1 reference

13 June 2017

publication date

2 May 2016

1 reference

13 June 2017

1 reference

13 June 2017

volume

38

1 reference

13 June 2017

issue

6

1 reference

13 June 2017

page(s)

857-874

1 reference

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

13 June 2017

cites work

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Calcimimetics with potent and selective activity on the parathyroid calcium receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

A re-evaluation of random-effects meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

GRADE guidelines: 7. Rating the quality of evidence--inconsistency

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

GRADE guidelines: 5. Rating the quality of evidence--publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

A Cost-Utility Analysis of Cinacalcet in Secondary Hyperparathyroidism in Five European Countries

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/0886022X.2016.1172468

10.3109/0886022X.2016.1172468

21 January 2018

Identifiers

DOI

1 reference

13 June 2017

1 reference